FY2025 EPS Estimates for MiMedx Group Lifted by Analyst

MiMedx Group, Inc (NASDAQ:MDXG) – Northland Capmk increased their FY2025 EPS estimates for shares of MiMedx Group in a report released on Thursday, July 31st. Northland Capmk analyst C. Byrnes now anticipates that the company will post earnings per share of $0.32 for the year, up from their previous forecast of $0.28. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Capmk also issued estimates for MiMedx Group’s FY2026 earnings at $0.34 EPS.

Several other brokerages also recently issued reports on MDXG. Wall Street Zen upgraded MiMedx Group from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Cantor Fitzgerald lifted their price target on MiMedx Group from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Thursday.

MiMedx Group Stock Down 0.4%

NASDAQ MDXG opened at $7.16 on Friday. The stock’s 50 day simple moving average is $6.44 and its 200 day simple moving average is $7.27. MiMedx Group has a one year low of $5.47 and a one year high of $10.14. The firm has a market cap of $1.06 billion, a PE ratio of 34.10 and a beta of 1.79. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.39 and a quick ratio of 4.13.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.04. MiMedx Group had a net margin of 8.84% and a return on equity of 23.03%. The company had revenue of $98.61 million during the quarter, compared to analyst estimates of $90.79 million.

Institutional Trading of MiMedx Group

Several hedge funds have recently modified their holdings of MDXG. Paradigm Capital Management Inc. NY lifted its holdings in MiMedx Group by 0.5% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company’s stock worth $45,082,000 after buying an additional 22,131 shares in the last quarter. Cannell Capital LLC raised its position in shares of MiMedx Group by 1.1% during the fourth quarter. Cannell Capital LLC now owns 3,639,545 shares of the company’s stock worth $35,012,000 after acquiring an additional 40,235 shares during the last quarter. First Light Asset Management LLC raised its position in shares of MiMedx Group by 3.3% during the first quarter. First Light Asset Management LLC now owns 3,453,074 shares of the company’s stock worth $26,243,000 after acquiring an additional 109,213 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of MiMedx Group by 18.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company’s stock valued at $17,360,000 after acquiring an additional 280,327 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in MiMedx Group by 15.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,802,364 shares of the company’s stock valued at $17,338,000 after acquiring an additional 238,075 shares during the last quarter. 79.15% of the stock is owned by institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.